Article
Immunology
Xiaohe Li, Ling Ma, Yuli Wei, Jinying Gu, Jingjing Liang, Shimeng Li, Yunyao Cui, Rui Liu, Hui Huang, Cheng Yang, Honggang Zhou
Summary: Cabozantinib shows potential as a treatment for acute lung injury and pulmonary fibrosis by improving pathological state, reducing inflammation, inhibiting fibrosis, and regulating key signaling pathways such as TLR4/NF-kappa B/NLRP3 and TGF-131/Smad3.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Immunology
Yang Miao, Xiaohe Li, Yue Yang, Jianwei Zhang, Li Chen, Qianyi Zhang, Wenqi Li, Ying Liu, Xianfeng Zhang, Ruimin Gu, Cheng Yang
Summary: In this study, it was found that Entrectinib effectively inhibits the development of pulmonary fibrosis by blocking TGF-β1 signaling, both in vitro and in vivo.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Jingjing Huang, Hydia Puente, Nancy E. E. Warening, Minghua Wu, Maureen D. D. Mayes, Harry Karmouty-Quintana, Shervin Assassi, Tingting W. W. Mills
Summary: This study found that phosphorylation of STAT6 increased in fibrotic skin samples from SSc patients and bleomycin-injected mice. Knockout of Stat6 in mice suppressed fibrotic cytokines expression and reduced collagen and fibronectin production. STAT6 inhibition also attenuated skin fibrosis in mice. Co-culture experiments further demonstrated the role of STAT6 in cytokine and fibrotic marker expression in skin epithelial cells and fibroblasts.
Article
Biochemistry & Molecular Biology
Hemat El-Sayed El-Horany, Marwa Mohamed Atef, Muhammad Tarek Abdel Ghafar, Mohamed. H. Fouda, Nahla Anas Nasef, Islam Ibrahim Hegab, Duaa S. Helal, Walaa Elseady, Yasser Mostafa Hafez, Rasha Youssef Hagag, Monira Abdelmoaty Seleem, Mai Mahmoud Saleh, Doaa A. Radwan, Amal Ezzat Abd El-Lateef, Rania Nagi Abd-Ellatif
Summary: This study aimed to evaluate the ameliorative effect of empagliflozin (EMPA) against bleomycin (BLM)-induced pulmonary fibrosis (PF) and the potential mechanisms. The results showed that EMPA could improve lung tissue damage, reduce lung index, hydroxyproline content, and transforming growth factor beta 1 levels, and have anti-inflammatory, antioxidative stress, and anti-DNA fragmentation effects. It also protected lung cells by enhancing autophagy and modulating sestrin2/AMPK/Nrf2/HO-1 signaling pathway. Therefore, EMPA may be a potential drug for the treatment of PF.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Yuanyuan Han, Mao Jiang, Rongling He, Xin Lv, Xiaohua Liao, Yijun He, Fan Zhang, Lingzhi Long, Guoliang Jiang, Zhangzhe Peng, Lijian Tao, Gaoyun Hu, Jie Meng
Summary: The study found that the newly synthesized drug MFD can alleviate lung fibrosis by suppressing TGF-beta/Smad2 and MAPK pathways, reducing cell apoptosis and EMT in the fibrotic process.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Miriam S. Hohmann, David M. Habiel, Milena S. Espindola, Guanling Huang, Isabelle Jones, Rohan Narayanan, Ana Lucia Coelho, Justin M. Oldham, Imre Noth, Shwu-Fan Ma, Adrianne Kurkciyan, Jonathan L. McQualter, Gianni Carraro, Barry Stripp, Peter Chen, Dianhua Jiang, Paul W. Noble, William Parks, John Woronicz, Geoffrey Yarranton, Lynne A. Murray, Cory M. Hogaboam
Summary: IPF is characterized by elevated levels of CCR10 and CCL28 in lung tissue, with CCR10(+) cells promoting pulmonary fibrosis and EphA3 mAb targeting these cells reducing fibrosis.
Article
Immunology
Yifei Lu, Yihan Zhang, Dengfeng Xu, Yuanyuan Wang, Da Pan, Hui Xia, Guiju Sun
Summary: This article aims to explore the role of DXM in the occurrence and development of pulmonary fibrosis at different stages. The results of the study indicate that long-term low-dose intake of DXM has therapeutic effects on pulmonary fibrosis induced by bleomycin.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Daisuke Akahori, Naoki Inui, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Takafumi Suda
Summary: The study showed that under hypoxic conditions, specific protein expression in pulmonary endothelial cells was affected, leading to enhanced fibrogenesis-related damage, and this phenomenon was more pronounced in patients with pulmonary fibrosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Lan Wang, Kai Xu, Ningdan Wang, Linke Ding, Wenyu Zhao, Ruyan Wan, Weiming Zhao, Xiaoshu Guo, Xin Pan, Juntang Yang, Ivan Rosas, Guoying Yu
Summary: This study demonstrates that fenbendazole (FBZ) treatment has an inhibitory effect on bleomycin-induced lung fibrosis in mice, as well as inhibiting the proliferation and migration of human embryo lung fibroblasts in vitro. The mechanism underlying this effect involves inhibition of glucose consumption, moderation of glycolytic metabolism, activation of adenosine monophosphate-activated protein kinase (AMPK), and reduction of the activation of the mammalian target of rapamycin (mTOR) pathway, ultimately leading to the inhibition of fibroblast-to-myofibroblast differentiation and collagen synthesis induced by transforming growth factor-beta (TGF-beta 1).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Lin Pan, Yiju Cheng, Wenting Yang, Xiao Wu, Honglan Zhu, Meigui Hu, Yuquan Zhang, Menglin Zhang
Summary: Nintedanib is an effective drug for treating idiopathic pulmonary fibrosis (IPF) by inhibiting PDGF, b-FGF, and VEGF signaling pathways. This study investigated the therapeutic efficacy of nintedanib in bleomycin-mediated pulmonary fibrosis (PF) mice through the PI3K/Akt/mTOR pathway. Results showed that nintedanib improved bleomycin-induced lung injury and reduced pulmonary fibrosis by inhibiting the PI3K/Akt/mTOR pathway and apoptosis. Histopathological analysis further confirmed the attenuating effect of nintedanib on bleomycin-induced lung injury.
Article
Plant Sciences
Lingling Deng, Boshu Ouyang, Hanlin Shi, Fangyong Yang, Shihuan Li, Cong Xie, Wenjing Du, Lingli Hu, Ying Wei, Jingcheng Dong
Summary: Numerous studies have shown that Icariside II (ISE II) plays a significant role in preventing and treating various chronic diseases such as diabetes and fibrosis in different organs. This study investigated the therapeutic effect of ISE II in models of pulmonary fibrosis and found that it inhibits pro-fibrotic macrophage polarization by modulating the WNT/β-catenin signaling pathway.
JOURNAL OF ETHNOPHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Ying Jiang, Feifei Hu, Ming Li, Qiao Li
Summary: This study demonstrates that tanshinone IIA (TAN IIA) can inhibit skin fibrosis in systemic sclerosis (SSc) by modulating the TGF-beta/Smad and MAPK/ERK signaling pathways. TAN IIA significantly improves skin thickness and collagen deposition in a mouse model of SSc, and inhibits the proliferation of skin fibroblasts derived from SSc patients by inducing cell cycle arrest and promoting apoptosis.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
(2023)
Article
Cell & Tissue Engineering
XiaoLing Cui, XiaoTan Wang, Jie Wen, Xiao Li, Nan Li, XuXiao Hao, BaoXiang Zhao, Xunwei Wu, JunYing Miao
Summary: This study demonstrates that the small chemical molecule CPP can effectively induce the differentiation of human dermal fibroblasts (HDFs) into vascular endothelial cells (VECs). The results show that CPP treatment leads to morphological changes in HDFs and upregulation of VEC markers. Additionally, in vitro and in vivo experiments confirm that CPP-induced HDFs possess the functions of VECs. The induction of VEC differentiation by CPP is associated with the increased expression of pro-angiogenic factors.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Biochemistry & Molecular Biology
Hana Storkanova, Lenka Storkanova, Adela Navratilova, Viktor Becvar, Hana Hulejova, Sabina Oreska, Barbora Hermankova, Maja Spiritovic, Radim Becvar, Karel Pavelka, Jiri Vencovsky, Joerg H. W. Distler, Ladislav Senolt, Michal Tomcik
Summary: This study demonstrates the crucial role of Hsp90 in the pathophysiology of SSc and identifies it as a potential target for fibrosis treatment. Treatment with the Hsp90 inhibitor 17-DMAG effectively prevents and reverses dermal fibrosis, showing significant anti-fibrotic and anti-inflammatory properties.
Article
Cell Biology
Alessandro Ianni, Michael Hofmann, Poonam Kumari, Shahriar Tarighi, Hamza M. Al-Tamari, Andre Goergens, Bernd Giebel, Hendrik Nolte, Marcus Krueger, Isabelle Salwig, Soni Savai Pullamsetti, Andreas Guenther, Andre Schneider, Thomas Braun
Summary: Idiopathic pulmonary fibrosis (IPF) is a highly aggressive and poorly understood lung disease, with lung epithelial cells playing a critical role in its initiation and progression. NUMB protein is necessary for the pathological activation of beta-catenin signaling in lung epithelial cells following bleomycin-induced injury. Depletion of Numb and Numblike reduces fibrotic lesion accumulation, preserves lung function, and increases survival rates in mice treated with bleomycin.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)